In this study, levels of anti-VSA (CD36- and ICAM-1-binding parasites) antibodies in plasma samples from CM patients during the active disease phase (D0) and seven days after treatment was commenced (D7) were quantitatively determined by flow cytometry and compared with the levels in UM control patients. Here, ICAM1 is linked to cutaneous mastocytosis.